Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Nikolaus Benjamin WagnerMax M LendersKathrin KühlLydia ReinhardtFiona AndréMilena DuddaNatalie RingChiara EbelRamon StägerCaroline ZellwegerRoland LangMichael PaarPhilipp GussekGeorg RichtigSuzan H StürmerSusanne KimeswengerAngela OellingerAndrea ForschnerUlrike LeiterBenjamin WeideMaximilian GassenmaierAmadeus SchraagBernhard KlumppWolfram HoetzeneckerCarola BerkingErika RichtigMirjana ZiemerJohanna ManganaPatrick TerheydenCarmen LoquaiVan Anh NguyenChristoffer GebhardtFriedegund MeierStefan DiemAntonio CozzioLukas FlatzMartin RöckenClaus GarbeThomas K EigentlerPublished in: Journal for immunotherapy of cancer (2022)
High pretreatment MGR is an independent strong prognostic biomarker associated with unfavorable survival of melanoma patients receiving anti-PD-1 antibodies. Further investigations are warranted to assess the predictive impact of MGR in distinct systemic therapeutic regimens.